Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Study protocol

Study protocol for a cluster-randomized trial to compare human papillomavirus based cervical cancer screening in community-health campaigns versus health facilities in western Kenya

Authors: Megan J. Huchko, James G. Kahn, Jennifer S. Smith, Robert A. Hiatt, Craig R. Cohen, Elizabeth Bukusi

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Despite guidelines for cervical cancer prevention in low-resource countries, a very small proportion of women in these settings undergo screening, and even fewer women are successfully treated. Using pilot data from western Kenya and World Health Organization recommendations, we developed a protocol to implement evidence-based cervical cancer screening and linkage to treatment strategies to the rural communities. We describe the protocol for a cluster-randomized trial to compare two implementation strategies for human-papillomavirus (HPV)-based cervical cancer screening program using metrics described in the RE-AIM (reach, efficacy, adaption, implementation and maintenance) framework.

Methods

The study is a three-year, two-phase cluster-randomized trial in 18 communities in western Kenya. During Phase 1, six control communities were offered screening in health facilities; and six intervention communities were offered screening in community health campaigns. Screening was done with human-papillomavirus testing through self-collected specimens. Phase 1 ended and we are working in partnership with communities to further contextualize the implementation strategy for screening, and develop an enhanced linkage to treatment plan. This plan will be tested in an additional six communities in Phase 2 (enhanced intervention). We will compare the reach, efficacy, cost-effectiveness and adaptability of the implementation strategies.

Discussion

Effective low-cost cervical cancer prevention technologies are becoming more widely available in low- and middle-income countries. Despite increasing government support for cervical cancer prevention, there remains a sizeable gap in service availability. We will use implementation science to identify the most effective strategies to fill this gap through development of context-specific evidence-based solutions. This protocol design and results can help guide implementation of cervical cancer screening in similar settings, where women are most underserved and at highest risk for disease.

Trial registration

This trial is registered at ClinicalTrials.​gov, NCT02124252.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal international du cancer. 2010;127(12):2893–917.CrossRefPubMed
2.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMed
3.
Sankaranarayanan R, Swaminathan R, Jayant K, Brenner H. An overview of cancer survival in Africa, Asia, the Caribbean and central America: the case for investment in cancer health services. IARC Sci Publ. 2011;162:257–91.
4.
World Health Organization. Comprehensive cervical cancer prevention and control: a healthier future for girls and women. In: WHO Guidance Note. Geneva: World Health Organization; 2013.
5.
Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360(14):1385–94.CrossRefPubMed
6.
Akinyemiju TF. Socio-economic and health access determinants of breast and cervical cancer screening in low-income countries: analysis of the world health survey. PLoS One. 2012;7(11):e48834.CrossRefPubMedPubMedCentral
7.
Anorlu RI. Cervical cancer: the sub-Saharan African perspective. Reprod Health Matters. 2008;16(32):41–9.CrossRefPubMed
8.
Sankaranarayanan R, Rajkumar R, Esmy PO, Fayette JM, Shanthakumary S, Frappart L, Thara S, Cherian J. Effectiveness, safety and acceptability of ‘see and treat’ with cryotherapy by nurses in a cervical screening study in India. Br J Cancer. 2007;96(5):738–43.CrossRefPubMedPubMedCentral
9.
10.
Kenya--World Health Survey. In.: World Health Institution; 2003.
11.
Rosser JI, Hamisi S, Njoroge B, Huchko MJ. Barriers to cervical cancer screening in rural Kenya: perspectives from a provider survey. J Community Health. 2015;
12.
Huchko M, Maloba M. Increasing access to cervical cancer screening: mobile screening on Mfangano Island, suba, Kenya. In: Cervical cancer screening and prevention quarterly report. Kisumu: Kenya Medical Research Institute; 2013.
13.
Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, Petersen ML, Thirumurthy H, Kamya MR, Havlir DV, et al. Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda. PLoS One. 2012;7(8):e43400.CrossRefPubMedPubMedCentral
14.
Lassi ZS, Haider BA, Bhutta ZA. Community-based intervention packages for reducing maternal and neonatal morbidity and mortality and improving neonatal outcomes. Cochrane Database Syst Rev. 2010;11:CD007754.
15.
Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, Sabin ML, Makhlouf-Obermeyer C, De Filippo Mack C, Williams P, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS One. 2012;7(2):e30216.CrossRefPubMedPubMedCentral
16.
Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322–7.CrossRefPubMedPubMedCentral
17.
18.
Sudenga SL, Rositch AF, Otieno WA, Smith JS. Knowledge, attitudes, practices, and perceived risk of cervical cancer among Kenyan women: brief report. Int J Gynecol Cancer. 2013;23(5):895–9.CrossRefPubMedPubMedCentral
19.
Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright TC Jr. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA, J. Am. Med. Assoc. 2005;294(17):2173–81.CrossRef
20.
Denny L, Kuhn L, CC H, Tsai WY, Wright TC Jr. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst. 2010;102(20):1557–67.CrossRefPubMed
21.
Stewart DE, Gagliardi A, Johnston M, Howlett R, Barata P, Lewis N, Oliver T, Mai V. Self-collected samples for testing of oncogenic human papillomavirus: a systematic review. J Obstet Gynaecol Can. 2007;29(10):817–28.CrossRefPubMed
22.
Zhao FH, Lewkowitz AK, Chen F, Lin MJ, SY H, Zhang X, Pan QJ, Ma JF, Niyazi M, Li CQ, et al. Pooled analysis of a self-sampling HPV DNA test as a cervical cancer primary screening method. J Natl Cancer Inst. 2012;104(3):178–88.CrossRefPubMedPubMedCentral
23.
Petignat P, Faltin DL, Bruchim I, Tramer MR, Franco EL, Coutlee F. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol. 2007;105(2):530–5.CrossRefPubMed
24.
Trope LA, Chumworathayi B, Blumenthal PD. Feasibility of community-based careHPV for cervical cancer prevention in rural Thailand. J Low Genit Tract Dis. 2013;17(3):315–9.CrossRefPubMed
25.
Ortiz AP, Alejandro N, Perez CM, Otero Y, Soto-Salgado M, Palefsky JM, Tortolero-Luna G, Romaguera J. Acceptability of cervical and anal HPV self-sampling in a sample of Hispanic women in Puerto Rico. P R Health Sci J. 2012;31(4):205–12.PubMedPubMedCentral
26.
Igidbashian S, Boveri S, Spolti N, Radice D, Sandri MT, Sideri M. Self-collected human papillomavirus testing acceptability: comparison of two self-sampling modalities. J Women's Health (Larchmt). 2011;20(3):397–402.CrossRef
27.
Ogilvie GS, Mitchell S, Sekikubo M, Biryabarema C, Byamugisha J, Jeronimo J, Miller D, Steinberg M, Money DM. Results of a community-based cervical cancer screening pilot project using human papillomavirus self-sampling in Kampala, Uganda. Int. J. Gynaecol. Obstet. :J. Int. Fed. Gynaecol. Obstet. 2013;122(2):118–23.CrossRef
28.
Rositch AF, Gatuguta A, Choi RY, Guthrie BL, Mackelprang RD, Bosire R, Manyara L, Kiarie JN, Smith JS, Farquhar C. Knowledge and acceptability of pap smears, self-sampling and HPV vaccination among adult women in Kenya. PLoS One. 2012;7(7):e40766.CrossRefPubMedPubMedCentral
29.
Darlin L, Borgfeldt C, Forslund O, Henic E, Hortlund M, Dillner J, Kannisto P. Comparison of use of vaginal HPV self-sampling and offering flexible appointments as strategies to reach long-term non-attending women in organized cervical screening. J Clin Virology. 2013;58(1):155–60.CrossRef
30.
Sancho-Garnier H, Tamalet C, Halfon P, Leandri FX, Retraite LL, Djoufelkit K, Heid P, Davies P, Piana L. HPV self-sampling or the Pap-smear: A randomized study among cervical screening nonattenders from lower socioeconomic groups in France. Int J Cancer. 2013;133(11):2681–7.PubMed
31.
Leniz J, Barriga MI, Lagos M, Ibanez C, Puschel K, Ferreccio C. HPV vaginal self-sampling among women non-adherent to Papanicolaou screening in Chile. Salud Publica Mex. 2013;55(2):162–9.CrossRefPubMed
32.
Levinson KL, Abuelo C, Salmeron J, Chyung E, Zou J, Belinson SE, Wang G, Ortiz CS, Vallejos CS, Belinson JL. The Peru cervical cancer prevention study (PERCAPS): the technology to make screening accessible. Gynecol Oncol. 2013;129(2):318–23.CrossRefPubMedPubMedCentral
33.
Snijders PJ, Verhoef VM, Arbyn M, Ogilvie G, Minozzi S, Banzi R, van Kemenade FJ, Heideman DA, Meijer CJ. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int. J. Cancer J Int cancer. 2013;132(10):2223–36.CrossRef
34.
Virtanen A, Nieminen P, Luostarinen T, Anttila A. Self-sample HPV tests as an intervention for nonattendees of cervical cancer screening in Finland: a randomized trial. Cancer Epidemiol. Biomark. Prev. : Publ. Am. Assoc. Cancer Res, Am. Soc. Prev. Oncol. 2011;20(9):1960–9.CrossRef
35.
Odeny TA, Bailey RC, Bukusi EA, Simoni JM, Tapia KA, Yuhas K, Holmes KK, McClelland RS. Text messaging to improve attendance at post-operative clinic visits after adult male circumcision for HIV prevention: a randomized controlled trial. PLoS One. 2012;7(9):e43832.CrossRefPubMedPubMedCentral
36.
Odeny TA, Bailey RC, Bukusi EA, Simoni JM, Tapia KA, Yuhas K, Holmes KK, McClelland RS. Effect of text messaging to deter early resumption of sexual activity after male circumcision for HIV prevention: a randomized controlled trial. J Acquir Immune Defic Syndr. 2014;65(2):e50–7.CrossRefPubMedPubMedCentral
37.
38.
Santesso N, Schunemann H, Blumenthal P, De Vuyst H, Gage J, Garcia F, Jeronimo J, Lu R, Luciani S, Quek SC, et al. World Health Organization guidelines: use of cryotherapy for cervical intraepithelial neoplasia. Int. J. Gynaecol. Obstet. 2012;118(2):97–102.CrossRefPubMed
39.
Sauvaget C, Muwonge R, Sankaranarayanan R. Meta-analysis of the effectiveness of cryotherapy in the treatment of cervical intraepithelial neoplasia. Int J Gynaecol Obstet. 2013;120(3):218–23.CrossRefPubMed
40.
World Health Organization. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. In: Organization WH, editor. . Geneva: World Health Organization; 2013.
41.
Chamie G, Clark TD, Kabami J, Kadede K, Ssemmondo E, Steinfeld R, Lavoy G, Kwarisiima D, Sang N, Jain V, et al. A hybrid mobile approach for population-wide HIV testing in rural east Africa: an observational study. Lancet HIV. 2016;3(3):e111–9.CrossRefPubMedPubMedCentral
42.
Cane J, O'Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci. 2012;7:37.CrossRefPubMedPubMedCentral
43.
Rosser JI, Njoroge B, Huchko MJ. Changing knowledge, attitudes, and behaviors regarding cervical cancer screening: The effects of an educational intervention in rural Kenya. Patient Educ Couns. 2015;98(7):884–9.CrossRefPubMedPubMedCentral
44.
WHO. Comprehensive cervical cancer prevention and control: a healthier future for girls and women. WHO guidance note. Geneva, Switzerland: World Health Organization; 2013.
45.
46.
Sustainable East Africa Research in Community Health (SEARCH); baseline census data. PI: Diane Havlir. Source: Personal communication with study coordinator, R. Steinfeld. In.; 2013.
47.
Kotwani P, Balzer L, Kwarisiima D, Clark TD, Kabami J, Byonanebye D, Bainomujuni B, Black D, Chamie G, Jain V, et al. Evaluating linkage to care for hypertension after community-based screening in rural Uganda. Tropical Med Int Health. 2014;19(4):459–68.CrossRef
48.
Metadata
Title
Study protocol for a cluster-randomized trial to compare human papillomavirus based cervical cancer screening in community-health campaigns versus health facilities in western Kenya
Authors
Megan J. Huchko
James G. Kahn
Jennifer S. Smith
Robert A. Hiatt
Craig R. Cohen
Elizabeth Bukusi
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3818-z

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Correspondence

Does hair dye use really increase the risk of prostate cancer?

Research article

Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States

Research article

BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study

Study protocol

Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: a study protocol

Research article

Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non–small-cell lung cancer

Research article

Identification of endonuclease domain-containing 1 as a novel tumor suppressor in prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits